- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Cynthia X. Ma, MD, PhD | Authors
Cynthia Ma, MD, PhD, Discusses Results From a Phase 2 Trial of Neratinib/Fulvestrant in HER2-Mutant Breast Cancer
July 22, 2021
Cynthia Ma, MD, PhD, explains key efficacy findings regarding HER-targeted therapy to treat patients with HER2-mutant breast cancer.
Cynthia Ma, MD, PhD, Discusses HER2-Targeted Therapy for Patients with HER2-Mutant Breast Cancer
July 12, 2021
An expert in treating breast cancer discusses potential therapy options for patients with HER2-mutant.
Cynthia X. Ma, MD, PhD, on Benefits of Attendance at AACR
May 30, 2021
CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, following the American Association for Cancer Research Annual Meeting 2021 about the benefits of the meeting to clinical trial investigators.
Cynthia X. Ma, MD, PhD, on Potential Immunotherapy Options for Patients With Metastatic Breast Cancer
May 22, 2021
CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 about data supporting the potential use of the exemestane/leuprolide acetate plus pembrolizumab combination.
The Cancer Genome Atlas: Clinical Applications for Breast Cancer
December 15, 2013
This article aims to provide an overview of The Cancer Genome Atlas findings, with a particular focus on their potential biological relevance and therapeutic implications.
The Natural History of Hormone Receptor–Positive Breast Cancer: Attempting to Decipher an Intriguing Concept
August 10, 2012
It is time to develop more active treatments in the early-disease setting that actually eradicate ER-positive breast cancer before new mutations and secondary resistance have a chance to develop. In this regard, standard chemotherapy is not the answer.
PARP Inhibitors and Their Evolving Role in Breast Cancer
October 12, 2011
Poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors are designed to exploit the “synthetic lethality” concept for cancer therapy.
Predicting Endocrine Therapy Responsiveness in Breast Cancer
February 15, 2009
This article reviews ongoing progress in the effort to identify predictors of endocrine therapy responsiveness for breast cancer and discusses the value of “pre-treatment” vs “on-treatment” tumor profiling for predicting outcomes.